


RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX0499US.NP  
Inventors: Fan et al.  
Serial No.: 10/593,799  
Filing Date: August 6, 2007  
Examiner: Blanchard, David J.  
Customer No.: 32800  
Group Art Unit: 1643  
Confirmation No.: 2565  
Title: LNG105 Antibody Composition and Methods  
of Use, and Use of LNG105 to Assess Lung  
Cancer Risk

Electronically Submitted via EFS-Web  
Date: September 7, 2010

I hereby certify that this paper is being electronically  
submitted on the date indicated above to the  
Commissioner for Patents, U.S. Patent &  
Trademark Office.

By   
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents  
U.S. Patent & Trademark Office

Dear Sir:

**Reply under 37 C.F.R. 1.116**

This is a reply to the Final Rejection mailed September 4,  
2010 setting a three (3) month statutory period for response.  
Please enter the following amendments and remarks into the  
record.

**Amendments to the claims** are reflected in the listing of  
claims which begins on page 2 of this paper.

**Remarks** begin on page 6.